Get the Stockscreener App
2.10
1.45%
0.03
After Hours:
2.10
Aclaris Therapeutics Inc stock is traded at $2.10, with a volume of 747.70K.
It is up +1.45% in the last 24 hours and up +35.48% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
747.70K
Relative Volume:
0.69
Market Cap:
$227.50M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-4.0385
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
+8.81%
1M Performance:
+35.48%
6M Performance:
+13.51%
1Y Performance:
+77.97%
1-Day Range:
$2.07
$2.15
1-Week Range:
$1.93
$2.15
52-Week Range:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.10 | 224.25M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
What’s the recovery path for long term holders of Aclaris Therapeutics Inc.Quarterly Earnings Report & High Conviction Buy Zone Alerts - Newser
Will Aclaris Therapeutics Inc. benefit from rising consumer demandJuly 2025 Recap & Fast Moving Market Watchlists - خودرو بانک
Visual analytics tools that track Aclaris Therapeutics Inc. performanceQuarterly Trade Review & High Accuracy Trade Alerts - Newser
Will Aclaris Therapeutics Inc. outperform the market in YEARMarket Activity Recap & Short-Term Swing Trade Alerts - خودرو بانک
Aclaris Therapeutics to Present at Two Investor Conferences in September - MSN
Is Aclaris Therapeutics Inc.’s ROE strong enough2025 Short Interest & Entry and Exit Point Strategies - خودرو بانک
Is Aclaris Therapeutics Inc. likely to announce a buybackQuarterly Performance Summary & Weekly Top Stock Performers List - خودرو بانک
Will Aclaris Therapeutics Inc. face regulatory challenges2025 Short Interest & Weekly Breakout Stock Alerts - خودرو بانک
Can technical indicators confirm Aclaris Therapeutics Inc.’s reversalBear Alert & Low Risk High Win Rate Stock Picks - Newser
Aclaris Therapeutics Inc. recovery potential after sell off2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Aclaris Therapeutics Inc. stock outlook for YEARWeekly Profit Recap & AI Optimized Trade Strategies - Newser
Can Aclaris Therapeutics Inc. continue delivering strong returnsJuly 2025 Spike Watch & Long-Term Growth Plans - خودرو بانک
Aclaris Therapeutics Inc. stock momentum explainedJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - Newser
How sentiment analysis helps forecast Aclaris Therapeutics Inc.Market Movement Recap & Technical Confirmation Alerts - Newser
Can Aclaris Therapeutics Inc. recover in the next quarterMarket Performance Summary & AI Driven Price Forecasts - Newser
Market reaction to Aclaris Therapeutics Inc.’s recent news2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Will Aclaris Therapeutics Inc. continue its uptrendPortfolio Gains Report & Real-Time Volume Spike Alerts - Newser
What’s the MACD signal for Aclaris Therapeutics Inc.2025 Valuation Update & Daily Profit Maximizing Trade Tips - خودرو بانک
How to escape a deep drawdown in Aclaris Therapeutics Inc.2025 Bull vs Bear & Free Long-Term Investment Growth Plans - Newser
Is Aclaris Therapeutics Inc. stock ready for a breakoutGap Up & Free Technical Confirmation Trade Alerts - Newser
Aclaris at Cantor Global Healthcare: Strategic Pipeline Insights - Investing.com
Forecasting Aclaris Therapeutics Inc. price range with options dataTrade Entry Report & Reliable Price Action Trade Plans - Newser
Using data tools to time your Aclaris Therapeutics Inc. exitJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
Volatility clustering patterns for Aclaris Therapeutics Inc.2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Real time pattern detection on Aclaris Therapeutics Inc. stock2025 Institutional Moves & Detailed Earnings Play Strategies - Newser
Long term hold vs stop loss in Aclaris Therapeutics Inc.2025 Performance Recap & Free Technical Confirmation Trade Alerts - Newser
Aclaris Therapeutics Inc. stock trendline breakdown2025 Winners & Losers & Verified Technical Signals - Newser
Earnings visualization tools for Aclaris Therapeutics Inc.2025 Institutional Moves & Weekly High Potential Alerts - Newser
Is Aclaris Therapeutics Inc. a speculative investmentStop Loss & Weekly High Conviction Trade Ideas - خودرو بانک
What’s the beta of Aclaris Therapeutics Inc. stockPortfolio Update Report & Verified Short-Term Plans - خودرو بانک
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
Developing predictive dashboards with Aclaris Therapeutics Inc. dataJuly 2025 Levels & Real-Time Buy Signal Alerts - Newser
Aclaris Therapeutics Inc. stock daily chart insightsGold Moves & High Yield Equity Trading Tips - Newser
Is Aclaris Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Volume & Expert Curated Trade Setup Alerts - خودرو بانک
Aclaris Therapeutics Inc. Volume Confirms Breakout — Analysts Bullish2025 Retail Activity & Fast Gaining Stock Strategy Reports - beatles.ru
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):